US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(CSE:
QNTM
)
4.510
UNCHANGED
Last Price
Updated: 3:15 PM EDT, Sep 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about QNTM
< Previous
1
2
3
4
5
6
Next >
Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000
June 10, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Clarifies It Has Not Changed Its Name
June 03, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Finalizes $2.35 Million Settlement with Former CEO Raza Bokhari
May 30, 2025
Via
Investor Brand Network
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
May 30, 2025
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
May 29, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
May 28, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
May 21, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
May 20, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
May 19, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
May 16, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
May 12, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
May 05, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
April 24, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
April 22, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Issues Corporate Update
April 21, 2025
Via
Investor Brand Network
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
April 14, 2025
Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™
April 10, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
April 03, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
April 01, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
March 31, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
March 28, 2025
Via
ACCESS Newswire
Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
March 28, 2025
Completion of unbuzzd™ Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company’s Pipeline of Products and Assets
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors
March 27, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales
March 26, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
March 20, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
February 26, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
February 18, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
February 11, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
February 10, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
February 06, 2025
From
Quantum BioPharma
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
